{"nctId":"NCT00398983","briefTitle":"Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)","startDateStruct":{"date":"2006-08"},"conditions":["Acute Myelogenous Leukemia"],"count":50,"armGroups":[{"label":"Decitabine 20 mg/m^2","type":"EXPERIMENTAL","interventionNames":["Drug: Decitabine"]},{"label":"No Study Drug","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"Decitabine","otherNames":["Dacogen"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult patients (greater than 18 years) with acute myelogenous leukemia (AML) by World Health Organization (WHO) criteria (greater than 20% blasts) and unfavorable risk cytogenetics (including intermediate and poor risk categories) in first CR or complete remission without full platelet recovery (CRp)\n* Adult patients (greater than 18 years) in second or subsequent Complete Response (CR) (or CRp)\n* Patients in first CR (or CRp) may have received any induction chemotherapy regimen; they may have received post-remission consolidation therapy (except for transplant) prior to inclusion in this protocol\n* Patients in 2nd or subsequent CR (or CRp) may have received any appropriate salvage regimen before achieving CR and may have received further therapy before inclusion\n* Performance status of 0, 1, or 2\n* Adequate organ function with creatinine less than or equal to 2.0 mg/dL, bilirubin less than or equal to 3.5 mg/dL and aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) less than or equal to 3 times institutional upper limit of normal\n\nExclusion Criteria:\n\n* Pregnant or lactating; women of child-bearing potential (WOCBP) must have negative pregnancy test. WOCBP defined as not post-menopausal for 12 months or no previous surgical sterilization\n* Known to be HIV+\n* Active and uncontrolled disease/infection as judged by the treating physician\n* Unable or unwilling to sign the consent form\n* No other investigational therapy within the past 14 days","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Relapse-Free Response at 1 Year","description":"Relapse free response defined an absence of relapse at one year of follow up.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":20},"commonTop":["Neutropenia","Thrombocytopenia","Infection","Anemia","Fatigue"]}}}